Disclaimer: Based on my own research from publicly available material, I believe there is potential that the product is NanoDX™. Sensera as a component manufacturer has not stated the product name specifically, most likely due to NDAs. I urge everyone to conduct their own research to determine if they think NanoDX may or not be the product. There is no way of knowing 100% without company confirmation.
I have researched potential products that would match manufacturing specifications where Sensera would be likely to participate, based on their know-how and technology deployed to date. In addition to the timeline specified by Sensera in previous announcements of FDA (EUA) approval.
There are very limited products that deploy bio sensors in the detection of Coronavirus, NanoDX is the only product I could find that is close to a submission to the FDA for emergency use authorisation which coincides with Sensera's statements and timeline.
Sensera has tangible experience in the field of Biosensors and has deployed them in existing products such as Labs-On-Chips.
The NanoDX product utilises a Nano (Bio) Sensor and produces a result within 2 minutes from either saliva or blood sample.
The NanoDX product is being manufactured using patented Harvard University technology in the field of Biosensors. Sensera has a partnership with Harvard University (Wyss Institute) and developed Organs-On-Chips and Labs-On-Chips with Harvard University.
NanoDX are financially backed by
Shepherd Kaplan Krochuk, who manage over 6 billion USD in assets.
Below is some information on NanoDX:
Sources:
1.
Nanodx gets $18M to pursue fast, easy COVID-19, TBI tests; aims for market shortly
2.
BioDirection Closes $18M Series C Financing
3.
NanoDX Website
Now the interesting part. You ask, on what basis do you think the product Sensera is developing relates to NanoDX? Well, answers below!
1. Link with Harvard University (NanoDX/Sensera)
A)
"It adapted its nanotechnology platform that originally was in-licensed from Harvard University to develop a test to identify active SARS-CoV-2 antigen from a drop of blood or saliva."
B)
"NanoDx has built a powerful intellectual property position to protect its design, manufacturing process and use of biosensors which includes 14 Harvard University generated patents, 4 pending patent applications, 3 additional patent applications which will be filed shortly."
We know that Sensera has a partnership with Harvard University for innovation using MEMS and Sensors. In particular, Sensera has developed Organ-On-Chips and Labs-On-Chips with Harvard Univesity and their specialised biotechnology unit called Wyss Institute.
These innovations include Point of Care (PoC), Organs-On-Chips, diagnostics and Labs-On-Chips.
NanoDX admits to using existing patented sensor technology from Harvard University.
Sensera secures ‘revenue generating’ deal with Harvard University
https://*********.com.au/sensera-secures-revenue-generating-deal-harvard-university/
Sensera’s MEMS Mimic Human Organs Through Bioengineering
http://sensera.com/sensera-mems-mimic-human-organs-though-bioengineering/
Sensera expands microfluidic fabrication capabilities into new medical diagnostic applications
http://sensera.com/sensera-expands-...ies-into-new-medical-diagnostic-applications/
Interesting also to note the similarities in statements from NanoDX and Sensera:
NanoDX:
Sensera:
2. Location
Sensera manufacturing facility is based in Woburn, Massachusetts. ->
http://sensera.com/contact/
NanoDX are based in Southborough, Massachusetts. ->
https://nanodiagnostics.com/contact/
Distance between the two companies via vehicle is 36-42 minutes.
BioDirection Inc (NanoDX) moved their headquarters from Tucson, Arizona to Southborough, Massachusetts.
Coincidence? Only within 36-42 minutes of the Sensera HQ!
3. Tim Stucchi, Sensera General manager of MicroDevices
Tim Stucchi liking posts about NanoDX. In addition, NanoDX is one of his few interests on linkedin. The other interests are clients like Abiomed or publications relevant to the industry.
